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80The efﬁcacy and safety of vedolizumab, a humanized immunoglobulin G1 monoclonal antibody
against the integrin a4b7, was demonstrated in multicenter, phase 3, randomized, placebo-
controlled trials in patients with moderately to severely active ulcerative colitis (UC) or
Crohn’s disease. We analyzed data from 1 of these trials to determine the effects of vedolizumab
therapy in patients with UC, based on past exposure to anti–tumor necrosis factor (TNF) agents.81
82METHODS:83
84
85We performed a post hoc analysis data from the GEMINI 1 study, collected from 464 patients
who received vedolizumab or placebo but had not received a previous TNF antagonist (naive to
TNF antagonists) and 367 patients with an inadequate response, loss of response, or intoler-
ance to TNF antagonists (failure of TNF antagonists). Predeﬁned outcomes of GEMINI 1 were













99At Week 6, there were greater absolute differences in efﬁcacy between vedolizumab and pla-
cebo in patients naive to TNF antagonists than patients with failure of TNF antagonists,
although the risk ratios (RRs) for efﬁcacy were similar for each group. Week 6 rates of response
to vedolizumab and placebo were 53.1% and 26.3%, respectively, among patients naive to TNF
antagonists (absolute difference, 26.4%; 95% conﬁdence interval [CI], 12.4–40.4; RR, 2.0; 95%
CI, 1.3–3.0); these rates were 39.0% and 20.6%, respectively, in patients with failure of TNF
antagonists (absolute difference, 18.1%; 95% CI, 2.8–33.5; RR, 1.9; 95% CI, 1.1–3.2). During
maintenance therapy, the absolute differences were similar but the RR for efﬁcacy was higher
for patients with failure of TNF antagonists than for patients naive to TNF antagonists, for most
outcomes. Week 52 rates of remission with vedolizumab and placebo were 46.9% and 19.0%,
respectively, in patients naive to TNF antagonists (absolute difference, 28.0%; 95% CI,
14.9–41.1; RR, 2.5; 95% CI, 1.5–4.0) and 36.1% and 5.3%, respectively, in patients with failure of
TNF antagonists (absolute difference, 29.5%; 95% CI, 12.8–46.1; RR, 6.6; 95% CI, 1.7–26.5). No





105Vedolizumab demonstrated signiﬁcantly greater efﬁcacy as induction and maintenance therapy
for UC than placebo in patients naive to TNF antagonists and patients with TNF antagonist
failure. There were numerically greater treatment differences at Week 6 among patients
receiving vedolizumab who were naive to anti-TNF agents than patients with anti-TNF failure.
ClinicalTrials.gov no: NCT00783718.106107Keywords: GEMINI; Inﬂammatory Bowel Disease; Treatment Failure; Biologic-Naive.
108
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205Ulcerative colitis (UC) is a chronic disease thatresults from uncontrolled inﬂammation of the
colon. Patients experience bloody diarrhea, abdominal
cramps, fatigue, and impaired health-related quality of
life.1 Although no cure exists, tumor necrosis factor-a
(TNF) antagonist therapy has greatly improved medical
management. However, the most effective treatments
currently available fail to adequately control disease
activity in many patients. Approximately 50% of patients
with UC do not respond to induction therapy with TNF
antagonists2–4 or lose response over time such that after
1 year of treatment, clinical remission is observed in only
17% to 34% of patients.2,3,5 Furthermore, the risk of
serious infection (with immunosuppressants in general,
and TNF antagonists speciﬁcally) is an important
concern.6,7 Thus, alternative approaches to treatment
are needed.
Vedolizumab is a novel, gut-selective humanized
immunoglobulin G1 monoclonal antibody to the a4b7
integrin that inhibits adhesion of a gut-homing subset of T
lymphocytes to mucosal addressin cell adhesion molecule
1. This mechanism selectively downregulates gut inﬂam-
mation while preserving systemic immune responses.8–14
The efﬁcacy and safety of vedolizumab induction and
maintenance treatment were demonstrated in the phase 3
GEMINI 1 and GEMINI 2 studies of patients with moder-
ately to severely active UC or Crohn’s disease, respec-
tively.15 Here in the prespeciﬁed exploratory and post hoc
analyses of GEMINI 1 data, we report the efﬁcacy and
safety of vedolizumab in patient subgroups based on their




























These results are based on subgroup analyses of
data from the multicenter, phase 3, randomized,
placebo-controlled GEMINI 1 trial of vedolizumab in
patients with moderately to severely active UC
(ClinicalTrials.gov, NCT00783718). Details of the study
design are reported elsewhere.15 Brieﬂy, 374 patients
were randomized, in a 3:2 ratio, to receive intravenous
vedolizumab or placebo induction therapy on Days 1
and 15 (Cohort 1; induction intent-to-treat [ITT]
population) (Supplementary Figure 1B). To fulﬁll sam-
ple size requirements for the subsequent maintenance
trial, 521 additional patients were enrolled in an
open-label group (Cohort 2) and received the same
vedolizumab induction regimen as administered in the
blinded study. Disease activity was deﬁned using the
Mayo Clinic score (MCS), which includes assessment of
stool frequency, rectal bleeding, endoscopy, and physi-
cian’s global assessment. The complete MCS ranges
from 0 to 12, with higher scores indicating more active
disease. Eligible patients had UC for 6 months before
enrollment, MCS from 6 to 12, and endoscopicFLA 5.4.0 DTD  YJCGH54900_proof subscores of 2 within 7 days before the ﬁrst dose of
study drug, and evidence of disease extending 15 cm
proximal to the rectum.
Vedolizumab-treated patients from both cohorts with
a clinical response at Week 6 were rerandomized (1:1:1)
to receive vedolizumab every 8 weeks or every 4 weeks
or placebo beginning at Week 6 for up to 46 weeks
(maintenance ITT population) (Supplementary Figure 1).
Clinical response was deﬁned as a reduction in the MCS
of 3 points and 30% from baseline (Week 0), with
an accompanying decrease of 1 point in the rectal
bleeding subscore or absolute rectal bleeding subscore
of 0 or 1. Patients who failed to respond to vedolizumab
at Week 6 continued vedolizumab therapy every 4
weeks during maintenance. Patients who had received
placebo during induction continued to receive placebo
during maintenance or discontinued (Supplementary
Figure 1). Patients were evaluated at Weeks 2, 4, and
6 during induction therapy and every 4 weeks thereafter
until Week 52.15
As part of the eligibility criteria for GEMINI 1, pa-
tients had demonstrated, within the previous 5-year
period, an inadequate response to, loss of response
to, or intolerance of 1 of the following therapies:
corticosteroids (outside the United States only), immu-
nosuppressives (azathioprine or mercaptopurine), and/
or inﬂiximab, because this was the only TNF antagonist
approved for the treatment of UC at the time of enroll-
ment. An inadequate response to inﬂiximab was deﬁned
as signs and symptoms of active disease despite at least
one 4-week induction regimen of 2 doses of inﬂiximab
at 5 mg/kg intravenously, 2 weeks apart. Loss of
response was deﬁned as the recurrence of symptoms in
a patient who had previously beneﬁted from inﬂiximab,
and patients with intolerance had experienced
treatment-related toxicity (eg, an infusion-related reac-
tion, psoriasiform skin lesion, demyelination, congestive
heart failure, infection, or other clinically meaningful
adverse events). In the present analyses, the TNF-failure
population comprised an aggregate of patients with
inadequate response, loss of response, or intolerance to
prior TNF antagonist treatment as predeﬁned according
to data captured on the case report form at baseline
(Week 0) (Supplementary Figure 1B). For classiﬁcation
purposes, we arbitrarily declared in a hierarchical
fashion that an inadequate response was considered
worse than loss of response and loss of response was
considered worse than intolerance. However, patients
could have more than one type of failure and were
evaluated by each type of failure in the present analyses.
Finally, the TNF-naive population comprised patients
who had never received a TNF antagonist as deﬁned
according to data captured on the interactive voice
response system during screening and enrollment
(Supplementary Figure 1B). Patients with prior exposure
to a TNF antagonist without prior failure were excluded
from the analyses; patients without prior exposure on
the interactive voice response system, but who had prior28 October 2016  6:06 pm  ce CJ





























































293TNF antagonist failure on the case report form, were














































In GEMINI 1, the primary outcome measure for in-
duction therapy was a clinical response at Week 6.
Secondary outcome measures were clinical remission
(MCS of 2 and no subscore >1) and mucosal healing
(Mayo Clinic endoscopic subscore of 0 or 1) at Week 6.
The primary outcome for maintenance therapy was
clinical remission at Week 52. Secondary measures
were durable clinical response (clinical response at
both Weeks 6 and 52), durable clinical remission
(clinical remission at both Weeks 6 and 52), mucosal
healing at Week 52, and corticosteroid-free remission
at Week 52 in patients receiving corticosteroids at
baseline.
In prespeciﬁed exploratory and post hoc analyses,
the efﬁcacy outcomes were evaluated in the TNF-failure
and TNF-naive ITT populations, respectively. Compari-
sons between the treatment arms within each popula-
tion were made using descriptive statistical techniques.
Speciﬁcally, the absolute difference (AD) in percentages
for vedolizumab and placebo and the risk ratios (RRs)
were calculated for each of the dichotomous outcomes
along with 95% conﬁdence intervals (CIs). The AD was
calculated using adjusted percentages based on the
Cochran-Mantel-Haenszel chi-square test, with stratiﬁ-
cation according to (1) concomitant use of oral corti-
costeroids (yes/no), (2) previous exposure to a TNF
antagonist and/or concomitant immunosuppressant use
(yes/no), and additionally for Week 52 endpoints (3)
enrollment in Cohort 1 or Cohort 2 in the induction
phase. The RR was deﬁned as the probability of a suc-
cessful outcome with vedolizumab treatment divided by
the probability of a successful outcome with placebo,
adjusted for the randomization stratiﬁcation factors. A
RR >1 indicates greater efﬁcacy with vedolizumab. RRs
were considered signiﬁcant if the 95% CI did not
contain zero.16 Given that the vedolizumab every-8-
week and every-4-week dosing groups had similar
treatment outcomes in the overall study and are
generally considered to be clinically equivalent,15 the 2
groups were evaluated as a combined vedolizumab











Safety data included the incidence, severity, and type
of adverse events, and ﬁndings from laboratory tests and
physical examinations. Adverse events were classiﬁed by
preferred terms deﬁned by the Medical Dictionary for
Regulatory Activities, version 14.0,17 and analyzed in the
safety population, which included patients who receivedFLA 5.4.0 DTD  YJCGH54900_proof vedolizumab at any time during the study and patients
who received placebo only.
Adverse events were reported as the number of
patients experiencing the Medical Dictionary for Regu-
latory Activities preferred term per 1000 person-years
(PYs) of exposure. PYs of exposure up to the ﬁrst
occurrence of each adverse event were calculated using
Equation 1. For patients who did not experience the
event, PYs of exposure were calculated using Equation
2 to account for 16-weeks postdose for vedolizumab
clearance or using Equation 3 if the patient continued in
the open-label extension study (ClinTrials.gov,
NCT00790933). Thus, the total PYs of exposure differs
for each preferred term because the number of PYs
was truncated after a patient experienced the event of
interest.
Equation 1 : PYs ¼ ðAdverse event onset dateÞ
 ðDate of first doseÞ þ 1
Equation 2 : PYs ¼ ðDate of last doseÞ
þ ð16 weeks  7daysÞ
 ðDate of first doseÞ þ 1
Equation 3 : PYs ¼ ðDate of last doseÞ
 ðDate of first doseÞ þ 1Immunogenicity
Blood samples for the evaluation of antidrug anti-
bodies (ADA) were collected within 30 minutes before
dosing. Immunogenicity in the total GEMINI 1 popula-
tion was determined as described elsewhere.18 In post
hoc analyses, the development of ADA in the TNF-naive
and TNF-failure subpopulations was determined. The
proportions of patients who had 1 positive sample




In GEMINI 1, a total of 1406 patients were screened
and 895 were enrolled in the study and randomized to
treatment (Supplementary Figure 1). Approximately
half (52%; n ¼ 464) of participants were TNF antago-
nist naive and the remainder had been exposed to TNF
antagonist therapy, with 41% (n ¼ 367) of the total
enrolled population having failed therapy according to
the predeﬁned criteria. Of note, 74 patients (15, 15, and
44 from the placebo, vedolizumab Cohort 1, and Cohort28 October 2016  6:06 pm  ce CJ
















































































4282 treatment arms, respectively) had prior exposure
without prior failure; these patients were excluded
from the present analyses. Because the study protocol’s
predeﬁned criteria for TNF-naive and TNF-failure sta-
tus came from different sources (ie, the interactive
voice response system and case report form, respec-
tively), 10 patients (5, 2, and 3 from the placebo,
vedolizumab Cohort 1, and Cohort 2 treatment arms,
respectively) were included in both subgroups
(Supplementary Figure 1). When ranked by worst
outcome for the placebo group, vedolizumab Cohort 1,
and Cohort 2, most prior failures were caused by
inadequate response (46%, 54%, and 46%, respec-
tively) followed by loss of response (41%, 39%, and
37%, respectively) and intolerance (13%, 7%, and 16%,
respectively) (Table 1).
Patient demographics and disease characteristics at
Week 0 are summarized by induction treatment group
(Table 1) and maintenance ITT group (Supplementary
Table 1) for TNF-naive and TNF-failure patients. Over-
all, the baseline demographics were similar for patients
in the vedolizumab and placebo groups.Table 1. Patient Demographics and Disease Characteristics at
Characteristic
TNF-naive patients




Age, y, mean  SD 40.5  11.7 39.7  13.1
Male sex, n (%) 47 (62) 69 (53)
Weight, kg, mean  SD 70.0  18.8 69.2  16.6
BMI, kg/m2, mean  SD 24.3  5.7 24.1  4.7
Current smoker, n (%) 7 (9) 7 (5)
Disease duration, y, mean  SD 6.1  6.4 5.8  5.2
Mayo Clinic score, mean  SD 8.5  1.5 8.4  1.8
fCal, mg/g, mean  SD 2714  3408 2357  3595
Disease localization, n (%)
Proctosigmoiditis 10 (13) 14 (11)
Left-sided colitis 35 (46) 66 (51)
Extensive colitis 7 (9) 14 (11)
Pancolitis 24 (32) 36 (28)
Concomitant medications, n (%)
CS only 28 (37) 42 (32)
IS only 10 (13) 24 (18)
CS and IS 16 (21) 31 (24)
No CS and IS 22 (29) 33 (25)
Prednisone-equivalent dose, mg,
median (min, max)
20.0 (5.0–40.0) 20.0 (2.5–40.0)
Type of TNF failure, n (%)b
Inadequate response N/A N/A
Loss of response N/A N/A
Intolerance N/A N/A
BMI, body mass index; CRF, case report form; CS, corticosteroid; fCal, fecal calpr
not applicable; SD, standard deviation.
aTNF-naive patients were classiﬁed by data captured on the IVRS at screening and e
Patients without prior exposure on the IVRS, but who had prior TNF antagonist fa
bEach patient was counted only once according to his or her worst outcome. Inad
considered worse than intolerance.
FLA 5.4.0 DTD  YJCGH54900_proof Induction Treatment in Tumor Necrosis
Factor–Naive and Tumor Necrosis
Factor–Failure Patients
In both TNF-naive and TNF-failure subgroups, vedo-
lizumab therapy resulted in higher percentages of pa-
tients with clinical response, clinical remission, and
mucosal healing at Week 6 than treatment with placebo
(Table 2). TNF-naive patients had relatively higher rates
of treatment response to vedolizumab induction therapy
than those observed in the TNF-failure population;
however, the RRs were similar (Table 2). At Week 6, a
total of 53.1% of TNF-naive patients who received
vedolizumab had a clinical response (primary outcome
measure) versus 26.3% of those assigned to placebo
(AD: 26.4%; 95% CI, 12.4–40.4; RR: 2.0; 95% CI,
1.3–3.0). Corresponding response rates in the TNF-
failure population were 39.0% versus 20.6% (AD:
18.1%; 95% CI, 2.8–33.5; RR: 1.9; 95% CI, 1.1–3.2)
(Table 2). Similar observations were made for rates of
clinical remission and mucosal healing (Table 2). The













40.6  13.6 41.8  13.1 39.7  12.5 40.2  13.2
151 (59) 35 (56) 50 (61) 122 (55)
72.7  19.4 74.2  16.4 74.9  17.0 75.3  19.8
25.1  6.2 25.0  4.5 25.6  5.0 25.5  6.1
17 (7) 1 (2) 4 (5) 15 (7)
6.4  6.2 8.0  7.6 6.4  5.0 8.0  7.0
8.5  1.7 8.6  1.9 8.7  1.8 8.6  1.8
1493  1980 2196  3256 3008  4270 1306  1604
43 (17) 8 (13) 10 (12) 23 (10)
99 (38) 20 (32) 19 (23) 76 (34)
33 (13) 9 (14) 10 (12) 24 (11)
83 (32) 26 (41) 43 (52) 99 (45)
98 (38) 27 (43) 30 (37) 81 (36)
68 (26) 6 (10) 5 (6) 37 (17)
33 (13) 8 (13) 13 (16) 33 (15)
59 (23) 22 (35) 34 (41) 71 (32)
20.0 (0.6–80.0) 15.0 (5.0–30.0) 20.0 (5.0–30.0) 20.0 (1.0–176.3)
N/A 29 (46) 44 (54) 103 (46)
N/A 26 (41) 32 (39) 83 (37)
N/A 8 (13) 6 (7) 36 (16)
otectin; IS, immunosuppressant; IVRS, interactive voice response system; N/A,
nrollment. Prior TNF failure was deﬁned by data recorded on the CRF at Week 0.
ilure on the CRF were included in both TNF-naive and TNF-failure populations.
equate response was considered worse than lost response; lost response was





































Table 2.Outcome Measures at Week 6 and Week 52
Outcome
TNF-naivea TNF-failurea All patientsb














(95% CI)cPlacebo Vedolizumab Placebo Vedolizumab Placebo Vedolizumab
Week 6 n ¼ 76 n ¼ 130 n ¼ 63 n ¼ 82 n ¼ 149 n ¼ 225




































Week 52 n ¼ 79 n ¼ 145 n ¼ 38 n ¼ 83 n ¼ 126 n ¼ 247




















































n ¼ 43 n ¼ 83 n ¼ 23 n ¼ 45 n ¼ 72 n ¼ 143
Corticosteroid-free
remissioni












CRF, case report form; IVRS, interactive voice response.
aTNF-naive patients were classiﬁed by data captured on the IVRS at screening and enrollment. Prior TNF failure was deﬁned by data recorded on the CRF at Week 0. Patients without prior exposure on the IVRS, but who had
prior TNF antagonist failure on the CRF were included in both TNF-naive and TNF-failure populations.
bWeek 6 data for all patients previously reported in Feagan et al15 and are shown here for comparison; represents the total population, including patients who may have had prior exposure, but not failure to a TNF antagonist.
cAdjusted based on the Cochran-Mantel-Haenszel chi-square test, with stratiﬁcation according to (1) concomitant use of oral corticosteroids (yes/no), (2) previous exposure to TNF antagonist and/or concomitant immu-
nomodulator use (yes/no), and additionally for Week 52 endpoints (3) enrollment in Cohort 1 or Cohort 2 in the induction phase.
dDeﬁned as reduction in complete Mayo score of 3 points and 30% from baseline with an accompanying decrease in rectal bleeding subscore of 1 point or absolute rectal bleeding subscore of 1 point.
eDeﬁned as complete Mayo score of 2 points and no individual subscore >1 point.
fDeﬁned as Mayo endoscopic subscore of 1.
gDeﬁned as clinical response at both Weeks 6 and 52.
hDeﬁned as clinical remission at both Weeks 6 and 52.
























































































































































































































































































































































































































































































643TNF-failure patients was most apparent in patients with
loss of response to a TNF antagonist; however, results
from the subgroup analyses should be interpreted with












655Maintenance Treatment in Tumor Necrosis
Factor–Naive and Tumor Necrosis
Factor–Failure Patients
At Week 52, a signiﬁcantly higher percentage of
vedolizumab-treated patients were in clinical remission,
durable clinical remission, and corticosteroid-free
remission and had a durable clinical response and
mucosal healing than patients assigned to placebo
(Table 2). In distinction to the induction study, theFLA 5.4.0 DTD  YJCGH54900_proof magnitude of treatment difference between vedolizumab
and placebo was similar for both the TNF-naive and TNF-
failure populations for almost all outcomes, with the
exception that the AD for durable clinical response was
lower in TNF-failure patients (Table 2). In addition, the
RRs with vedolizumab exposure for the TNF-failure
subgroup were more than 2 times the RRs for the TNF-
naive subgroup for all Week 52 outcomes excluding
durable clinical response (Table 2).
For the primary outcome measure, 46.9% of TNF-
naive patients were in clinical remission after 52 weeks
of vedolizumab treatment versus 19.0% of those who
received placebo (AD: 28.0%; 95% CI, 14.9–41.1; RR: 2.5;
95% CI, 1.5–4.0). Corresponding values in the TNF-
failure population were 36.1% versus 5.3% (AD:
29.5%; 95% CI, 12.8–46.1; RR: 6.6; 95% CI, 1.7–26.5)
(Table 2). Among patients receiving corticosteroids atFigure 1. Induction end-
points in TNF-failure pa-
tients by type of failure.
Forest plots show differ-
ence from placebo and
95% CIs for percentages
of patients with (A) clinical
response, (B) clinical
remission, and (C)
mucosal healing at Week
6. Patients with more than
one type of TNF antago-
nist failure were evaluated
by each type of failure;
thus the number of pa-
tients in the subgroups
may total more than the
number of enrolled
patients.






























































































































































812baseline, 44.6% of TNF-naive patients were in remission
and corticosteroid-free following vedolizumab mainte-
nance treatment versus 18.6% of those who received
placebo (AD: 26.3%; 95% CI, 8.7–43.9; RR: 2.4; 95% CI,
1.2–4.7) (Table 2). Corresponding values for TNF-failure
patients were 26.7% versus 4.3% (AD: 21.3%; 95% CI,
1.7–40.8; RR: 5.9; 95% CI, 0.8–43.5) (Table 2). Results
for the every-8-week and every-4-week dosing groups
separately are given in Supplementary Table 2.
In general, although the numbers of patients in the
subgroups were small, efﬁcacy endpoints at Week 52
favored vedolizumab treatment over placebo irre-
spective of the type of TNF failure (Figure 2). However,
TNF-failure patients with loss of response had the lowest
percentages meeting Week 52 endpoints with mainte-
nance vedolizumab therapy than any other classiﬁcation
of failure (Figure 2).
Safety
No clinically important differences in safety were
observed between the vedolizumab and placebo treat-
ment groups (Table 3 and Supplementary Table 3). The
proportion of TNF-naive patients with adverse events
and serious adverse events with maintenance vedolizu-
mab therapy were 74% and 9%, respectively, versus
75% and 16%, respectively, for placebo (Table 3). The
proportion of TNF-failure patients with adverse events
and serious adverse events was 88% and 17%, respec-
tively, with vedolizumab and 84% and 11%, respectively,
with placebo (Table 3). When adjusted for exposure,
adverse events and serious adverse events occurred in
more patients per 1000 PYs with placebo than with
vedolizumab in both TNF-naive and TNF-failure sub-
groups (Table 3). Overall, more individual events
occurred with an exposure-adjusted incidence rate of
100 patients per 1000 PYs with vedolizumab treatment
in the TNF-failure population (ie, arthralgia, fatigue,
nausea, cough, oropharyngeal pain, and bronchitis) than
in patients who were TNF-naive (Table 3).
Immunogenicity
Among all patients treated with vedolizumab contin-
uously (ITT and non-ITT combined), 15 (6%) TNF-failure
patients were ADA-positive and 3 (1%) patients were
persistently positive (ie, had 2 or more consecutive ADA-
positive samples). Among those who were TNF antago-
nist naive, 9 (3%) had at least 1 ADA-positive sample and
3 (1%) patients were persistently ADA-positive.
Discussion
These analyses show that vedolizumab had a consis-
tent beneﬁt for inducing and maintaining clinical
response and remission in both TNF-naive and TNF-
failure patients with moderately to severely active UC.FLA 5.4.0 DTD  YJCGH54900_proof Furthermore, no increased rates of serious infections
were observed with vedolizumab treatment relative to
placebo in either subgroup. The data also highlight that,
in absolute terms, greater efﬁcacy was evident for
vedolizumab induction therapy in TNF-naive patients
than those who had previously failed a TNF antagonist.
The AD in Week 6 remission rates was higher in patients
who were TNF-naive (AD, 15.5%) compared with those
who had failed therapy (AD, 7.0%). In contrast, in the
maintenance phase of the trial, the AD in remission rates
observed between these populations and placebo was
the same supporting the notion that similar clinically
meaningful effects are observed among both TNF-failure
and TNF-naive populations.
It is notable that, in maintenance, the absolute
remission rates were substantially lower in the TNF-
failure population for both vedolizumab-treated and
placebo-treated patients. In the latter group, the rate of
remission at Week 52 was 5.3%. However, inspection of
the RRs for clinical remission at Week 52 is consistent
with the presence of a relatively greater response to
vedolizumab in the TNF-failure population (TNF-failure:
RR, 6.6; 95% CI, 1.7–26.5 vs TNF-naive, RR, 2.5; 95% CI,
1.5–4.0). This relative difference should be interpreted
with caution given that the comparison was not pre-
speciﬁed and the RR estimate for the TNF-failure popu-
lation is imprecise. The relatively low placebo response
rate in the TNF-failure group could be attributed to the
presence of a greater proportion of patients with more
refractory disease and poor prognostic factors, such as
pancolitis and long disease duration.19 However, the high
RR values with assignment to vedolizumab in this rela-
tively refractory group of patients is more difﬁcult to
explain. One possibility is that failure of a TNF antagonist
selected for a group of patients who were more likely to
respond to vedolizumab in the long term on a mecha-
nistic basis and therefore, had relatively poor results if
assigned to placebo during the maintenance phase of the
trial. This possibility should be evaluated in well-
designed translational medicine studies.
At the time of GEMINI 1 study enrollment, inﬂiximab
was the only TNF antagonist approved for the treatment
of UC. Although treatment options in the class now
include adalimumab3 and golimumab,4,5 experience in
Crohn’s disease and UC has documented relatively lower
efﬁcacy when these TNF antagonists are used as second-
line treatment for inﬂiximab-failure patients.20–22
Although largely speculative, several potential explana-
tions exist for this experience, including the possibility
that inﬂammation in these patients may be predomi-
nately driven by mechanisms other than TNF; that fail-
ure patients may be more likely to have poor
pharmacokinetics, which may be particularly problem-
atic for subcutaneously administered therapies; and that
development of immunogenicity to inﬂiximab may pre-
dispose patients to sensitization with other members
of the anti-TNF class.23,24 Although therapeutic drug
monitoring (ie, measurement of drug and ADA28 October 2016  6:06 pm  ce CJ
Figure 2.Maintenance
endpoints in TNF-failure
patients by type of failure.
Forest plots show differ-
ence from placebo and
95% CIs for percentages
of patients with (A) clinical
remission, (B) durable
clinical response, (C)
mucosal healing, (D) dura-
ble clinical remission, and
(E) corticosteroid-free
remission at Week 52.
Patients with more than
one type of TNF antago-
nist failure were evaluated
by each type of failure;
thus the number of
patients in the subgroups
may total more than the
number of enrolled pa-
tients. CS, corticosteroid.
FLA 5.4.0 DTD  YJCGH54900_proof  28 October 2016  6:06 pm  ce CJ





















































































































Table 3. Summary of Adverse Events Reported by TNF-Naive and TNF-Failure Patients (Maintenance Safety Population)
Event
TNF-naive patientsa TNF-failure patientsa
Placebob (n ¼ 76) Vedolizumabc (n ¼ 309) Placebob (n ¼ 63) Vedolizumabc (n ¼ 266)
Total PYd ¼ 42.98 days
Total PYd ¼ 236.42
days Total PYd ¼ 25.38 days


























Any adverse event 57 (75) 2832.2 228 (74) 2146.1 53 (84) 7283.0 233 (88) 4895.5
Any serious adverse event 12 (16) 310.1 28 (9) 121.8 7 (11) 297.3 44 (17) 274.1
Any serious infectione 3 (4) 72.3 4 (1) 17.0 2 (3) 80.3 8 (3) 47.2
Common adverse events (100 patients with event/1000 PY in any patient group shown)f
Exacerbation of UC 16 (21) 394.6 36 (12) 156.9 11 (17) 457.5 54 (20) 335.2
Nasopharyngitis 3 (4) 70.4 26 (8) 114.9 8 (13) 333.2 46 (17) 309.8
Headache 3 (4) 72.1 33 (11) 152.8 10 (16) 448.5 40 (15) 267.8
Arthralgia 3 (4) 72.7 22 (7) 97.1 5 (8) 208.9 28 (11) 174.8
Upper respiratory tract
infection
5 (7) 120.2 24 (8) 106.7 3 (5) 118.2 26 (10) 161.1
Fatigue 0 0.0 9 (3) 38.8 5 (8) 212.2 20 (8) 123.8
Nausea 6 (8) 145.5 16 (5) 70.0 7 (11) 310.1 20 (8) 121.9
Cough 5 (7) 124.0 14 (5) 61.2 2 (3) 79.4 18 (7) 111.2
Oropharyngeal pain 1 (1) 23.5 7 (2) 30.2 2 (3) 80.9 17 (6) 104.1
Bronchitis 1 (1) 23.3 7 (2) 30.0 4 (6) 172.8 17 (6) 102.9
Pyrexia 1 (1) 23.2 8 (3) 34.4 4 (6) 163.8 15 (6) 90.7
Vomiting 2 (3) 47.2 11 (4) 47.6 4 (6) 164.0 14 (5) 83.7
Abdominal pain 3 (4) 72.3 20 (6) 87.5 6 (10) 263.2 14 (5) 83.0
Back pain 3 (4) 72.1 10 (3) 43.0 3 (5) 124.4 12 (5) 72.0
Edema peripheral 1 (1) 23.7 3 (<1) 12.8 5 (8) 220.9 12 (5) 71.8
Anemia 6 (8) 146.4 23 (7) 102.2 6 (10) 256.3 12 (5) 71.6
Neutrophil count increased 1 (1) 23.2 3 (<1) 12.8 3 (5) 119.3 2 (<1) 11.7
Amnesia 1 (1) 23.4 0 0.0 3 (5) 123.2 0 0.0
CRF, case report form; ITT, intent-to-treat; IVRS, interactive voice response; PY, person-year; UC, ulcerative colitis.
aTNF-naive patients were classiﬁed by data captured on the IVRS at screening and enrollment. Prior TNF failure was deﬁned by data recorded on the CRF at Week 0.
Patients without prior exposure on the IVRS, but who had prior TNF antagonist failure on the CRF were included in both TNF-naive and TNF-failure populations.
bPatients received placebo during both the induction and maintenance phases (non-ITT).
cPatients received vedolizumab during both the induction and maintenance phases (non-ITT and ITT combined).
dPYs of exposure up to the ﬁrst occurrence of each adverse event were calculated from the date of event onset minus the date of ﬁrst dose plus 1 day. For patients
who did not experience the event, PYs of exposure were calculated as the date of last dose plus 16  7 days minus the date of ﬁrst dose plus 1 day or as the date
of last dose minus the date of ﬁrst dose plus 1 day if the patient continued in the open-label extension study (ClinTrials.gov, NCT00790933). Thus, the total PYs of
exposure for each preferred term could be different because the number of PYs was truncated after a patient experienced the event of interest.
eIncludes those reported under the “Infections and infestations” system organ class.
fRanked from highest to lowest incidence in vedolizumab-treated TNF-failure patients.




















































































































1044concentrations) is potentially valuable in managing pa-
tients with poor response to a TNF antagonist,25 very
little data are available on the value of switching be-
tween drug classes based on the results of therapeutic
drug monitoring.26 Randomized trials should be per-
formed comparing vedolizumab to the use of a second
TNF antagonist in TNF antagonist failure patients with
adequate serum drug concentrations.
Development of ADAs was low in both the TNF
antagonist-naive and previously exposed populations
(1% vs 1%). Although no association was demonstrated
in either group between use of concomitant immuno-
suppression and efﬁcacy, patients receiving these medi-
cations were numerically less likely to develop ADAs.27
Likewise, although no meaningful differences in trough
drug levels were observed between the subgroups,FLA 5.4.0 DTD  YJCGH54900_proof patients who developed ADAs had reduced vedolizumab
drug concentrations.27 Collectively, these observations
indicate that the combined use of immunosuppression
may be advantageous; however, results from a well-
designed purpose built trial, analogous to the SONIC l
trial28 are need before conclusions regarding this ques-
tion can be drawn.
Our study has some limitations. Speciﬁcally, the re-
sults are based on exploratory and post hoc analyses of
subpopulations from the GEMINI 1 study. Although
subgroup comparisons should generally be interpreted
cautiously, especially with the small numbers of patients
within the subtypes of TNF antagonist failure, the rela-
tively large number of TNF-naive and TNF-failure pa-
tients evaluated in total, the prospectively deﬁned
outcome measures, and the demonstration of analogous28 October 2016  6:06 pm  ce CJ
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1141ﬁndings with other biologics3 support the validity of
these conclusions for the 2 groups overall, which have
important clinical implications. Physicians should be
aware that failure of a TNF antagonist is a predictor
of poor prognosis29,30 and recognize the need to opti-
mize subsequent induction therapy in these patients.
Recently, multiple publications have emphasized the
importance of this concept in detail, and include such
strategies as coadministration of corticosteroids and
immunosuppressives,31–33 treating to a speciﬁc objec-
tively deﬁned target (eg, endoscopic healing),34 use of
therapeutic drug monitoring,25,35,36 and ensuring an
adequate duration of therapy.37,38 These speciﬁc strate-
gies should be evaluated in future vedolizumab studies.
Although it is alluring to compare these results with
those obtained in previous pivotal trials of TNF antago-
nists, we would caution against using such an approach
to determine relative efﬁcacy given the confounding ef-
fects of differences in patient populations, outcome def-
initions, and, notably, trial design. A direct comparison of
vedolizumab with adalimumab is currently underway
(ClinicalTrials.gov, NCT02497469). The results of such
studies will be critical in informing payors regarding the
relative value of these agents.
Overall, the results of the present study are consistent
with those reported previously15 and indicate that
vedolizumab could be considered as a viable ﬁrst-line
option for patients with UC who are TNF antagonist
treatment naive, as well as safe and efﬁcacious induction
and maintenance therapy for patients with prior TNF
antagonist treatment failure.
Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
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Supplementary Figure 1. (A) GEMINI 1 study design and (B) patient populations. During the induction phase, patients
received double-blind vedolizumab or placebo or open-label vedolizumab at Weeks 0 and 2. Beginning at Week 6, patients
who had a response to vedolizumab received double-blind placebo or vedolizumab every 8 or every 4 weeks for the duration
of the maintenance phase. Patients who did not have a response at Week 6 could receive vedolizumab every 4 weeks and
those who received placebo during maintenance continued to receive placebo during the maintenance phase. Data for prior
TNF antagonist use were obtained from responses on the IVRS during screening and enrollment. Patients with prior TNF
antagonist failure were identiﬁed by data on the CRF at the baseline (Week 0) visit. Patients with prior exposure to a TNF
antagonist according to the IVRS and without prior failure according to the CRF were excluded from the analyses. aResponse
was deﬁned as a reduction in complete Mayo score of 3 points and 30% from baseline, with an accompanying decrease
in the rectal bleeding subscore of 1 point or absolute rectal bleeding subscore of 1. CRF, case report form; ITT,
intent-to-treat; IVRS, interactive voice response system; PBO, placebo; Q4W, every 4 weeks; Q8W, every 8 weeks; TNF, tumor
necrosis factor-a antagonist; VDZ, vedolizumab.
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Supplementary Figure 1. (continued).
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Supplementary Table 1. Patient Demographics and Baseline Disease Characteristics (Maintenance ITT Population)
Characteristic




Q8W (n ¼ 72)
Vedolizumab




Q8W (n ¼ 43)
Vedolizumab
Q4W (n ¼ 40)
Age, y, mean  SD 39.5  14.2 41.0  13.8 38.3  12.6 41.6  13.4 41.3  10.9 39.9  18.1
Male sex, n (%) 45 (57) 39 (54) 39 (53) 21 (55) 24 (56) 21 (53)
Weight, kg, mean  SD 71.3  18.3 76.1  19.0 70.3  16.9 81.2  23.8 79.1  18.1 72.7  17.4
BMI, kg/m2, mean  SD 24.9  5.5 26.4  6.3 24.1  4.9 27.4  7.0 27.0  6.3 24.8  4.6
Current smoker, n (%) 5 (6) 4 (6) 5 (7) 3 (8) 2 (5) 3 (8)
Disease duration, y, mean  SD 6.4  5.6 5.8  4.8 7.0  6.2 9.8  8.4 6.8  4.5 8.1  7.4
Mayo Clinic score, mean  SD 8.4  1.7 8.3  1.8 8.2  1.8 8.2  1.7 8.5  1.9 8.4  1.6
fCal, mg/g, mean  SD 2474  3441 1463  2205 1709  2931 1342  1595 2428  3805 1392  2345
Disease localization, n (%)
Proctosigmoiditis 8 (10) 13 (18) 10 (14) 1 (3) 5 (12) 3 (8)
Left-sided colitis 36 (46) 35 (49) 27 (37) 15 (39) 10 (23) 14 (35)
Extensive colitis 7 (9) 9 (13) 11 (15) 5 (13) 6 (14) 2 (5)
Pancolitis 28 (35) 15 (21) 25 (34) 17 (45) 22 (51) 21 (53)
Concomitant medications, n (%)
CS only 28 (35) 27 (38) 29 (40) 16 (42) 21 (49) 11 (28)
IS only 19 (24) 18 (25) 14 (19) 6 (16) 2 (5) 5 (13)
CS and IS 15 (19) 12 (17) 15 (21) 7 (18) 5 (12) 8 (20)
No CS and IS 17 (22) 15 (21) 15 (21) 9 (24) 15 (35) 16 (40)
Prednisone-equivalent dose, mg,
median (min, max)
20.0 (2.5–30.0) 20.0 (2.5–50.0) 17.5 (0.6–40.0) 15.0 (5.0–30.0) 20.0 (2.5–156.3) 15.0 (5.0–30.0)
Type of TNF failure, n (%)b
Inadequate response N/A N/A N/A 19 (50) 16 (37) 17 (43)
Loss of response N/A N/A N/A 13 (34) 16 (37) 15 (38)
Intolerance N/A N/A N/A 6 (16) 11 (26) 8 (20)
BMI, body mass index; CRF, case report form; CS, corticosteroid; fCal, fecal calprotectin; IS, immunosuppressant; ITT, intent-to-treat; IVRS, interactive voice
response; N/A, not applicable; Q4W, every 4 weeks; Q8W, every 8 weeks; SD, standard deviation; TNF, tumor necrosis factor-a antagonist.
aTNF-naive patients were classiﬁed by data captured on the IVRS at screening and enrollment. Prior TNF failure was deﬁned by data recorded on the CRF at
Week 0.
bEach patient was counted only once according to his or her worst outcome. Inadequate response was considered worse than lost response; lost response was
considered worse than intolerance.
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(95% CI)b RR (95% CI)b Patients, n (%)
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Placebon ¼ 79 n ¼ 72 n ¼ 73 n ¼ 38 n ¼ 43 n ¼ 40




































































n ¼ 43 n ¼ 39 n ¼ 44 n ¼ 23 n ¼ 26 n ¼ 19
Corticosteroid-free
remissiong
















CI, conﬁdence interval; ITT, intent-to-treat; Q4W, every 4 weeks; Q8W, every 8 weeks; RR, risk ratio; TNF, tumor necrosis factor-a antagonist.
aTNF-naive patients were classiﬁed by data captured on the IVRS at screening and enrollment. Prior TNF failure was deﬁned by data recorded on the CRF at Week 0. Patients without prior exposure on the IVRS, but who had
prior TNF antagonist failure on the CRF were included in both TNF-naive and TNF-failure populations.
bAdjusted based on the Cochran-Mantel-Haenszel chi-square test, with stratiﬁcation according to (1) concomitant use of oral corticosteroids (yes/no), (2) previous exposure to TNF antagonist and/or concomitant immu-
nomodulator use (yes/no), and (3) enrollment in Cohort 1 or Cohort 2 in the induction phase.
cDeﬁned as complete Mayo score of 2 points and no individual subscore >1 point.
dDeﬁned as reduction in complete Mayo score of 3 points and 30% from baseline with an accompanying decrease in rectal bleeding subscore of 1 point or absolute rectal bleeding subscore of 1 point (clinical response)
at both Weeks 6 and 52.
eDeﬁned as Mayo endoscopic subscore of 1.
fDeﬁned as clinical remission at both Weeks 6 and 52.













































































































































































































































































































































































































































































































































Supplementary Table 3. Summary of Adverse Events Reported by TNF-Naive and TNF-Failure Patients During
Induction Therapy
Event
TNF-naive patientsa TNF-failure patientsa
Placebo (n ¼ 76) Vedolizumab (n ¼ 388) Placebo (n ¼ 63) Vedolizumab (n ¼ 304)
Patients, n (%)
Any adverse event 29 (38) 149 (38) 39 (62) 164 (54)
Any serious adverse event 8 (11) 11 (3) 3 (5) 12 (4)
Any serious infectionb 2 (3) 2 (<1) 2 (3) 2 (<1)
Common adverse events (3% of patients in the vedolizumab group)c
Headache 1 (1) 26 (7) 6 (10) 27 (9)
Nasopharyngitis 1 (1) 9 (2) 4 (6) 17 (6)
Fatigue 0 5 (1) 3 (5) 12 (4)
Exacerbation of UC 6 (8) 8 (2) 3 (5) 11 (4)
Arthralgia 0 8 (2) 2 (3) 11 (4)
Nausea 2 (3) 10 (3) 3 (5) 9 (3)
Pyrexia 0 4 (1) 1 (2) 9 (3)
Cough 1 (1) 8 (2) 1 (2) 8 (3)
Upper respiratory tract infection 1 (1) 10 (3) 1 (2) 6 (2)
Anemia 3 (4) 12 (3) 3 (5) 2 (<1)
CRF, case report form; IVRS, interactive voice response; TNF, tumor necrosis factor-a antagonist; UC, ulcerative colitis.
aTNF-naive patients were classiﬁed by data captured on the IVRS at screening and enrollment. Prior TNF failure was deﬁned by data recorded on the CRF at Week
0. Patients without prior exposure on the IVRS, but who had prior TNF antagonist failure on the CRF, were included in both TNF-naive and TNF-failure populations.
bIncludes those reported under the “Infections and infestations” system organ class.
cRanked from highest to lowest incidence in vedolizumab-treated TNF-failure patients.
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